Form 4: Inotiv Executive Andrea Castetter Receives Stock and Options Grant

Andrea Castetter, SVP, Gen. Counsel & Secretary of Inotiv, Inc., reports receiving a grant of 20,000 restricted stock units and options to purchase 20,000 shares of common stock.

Summary

• Andrea Castetter, a senior executive at Inotiv, Inc., has reported changes in beneficial ownership of the company's securities.
• On August 10, 2024, Castetter received 20,000 restricted stock units, which will vest on June 18, 2026, contingent upon continued employment.
• Additionally, Castetter was granted options to purchase 20,000 shares of Inotiv's common stock at an exercise price of $1.61 per share.
• These options vest over three years: 40% on June 18, 2025, 30% on June 18, 2026, and 30% on June 18, 2027, also subject to continued employment.
• Following these transactions, Castetter directly owns 20,000 shares of Inotiv's common stock and options to purchase 20,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock options and restricted stock units is a standard practice and suggests confidence in the executive's continued contribution to the company. There are no immediate negative implications.

Positives

• The grant of restricted stock units and stock options to a key executive like Andrea Castetter could be seen as an incentive to align her interests with the long-term success of Inotiv, Inc.

Future Outlook

The vesting schedules for both the restricted stock units and stock options are contingent upon continued employment, suggesting an expectation of Castetter's continued service to the company.

Industry Context

Stock grants and options are common forms of executive compensation in publicly traded companies, particularly in the biotech and pharmaceutical services industries, to incentivize performance and retain key personnel. This is a standard practice to align executive interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are common in the pharmaceutical and biotechnology industries.
• Companies like Charles River Laboratories and Envigo (now part of Inotiv) also utilize similar compensation strategies to attract and retain talent.
• The vesting schedules and exercise prices are generally benchmarked against industry standards to ensure competitiveness and alignment with performance goals.

Stakeholder Impact

• Shareholders may view the stock and options grant as a positive sign, aligning executive interests with company performance.
• Employees may see this as a positive indicator of the company's commitment to its leadership team.

Key Dates